LAEKNA-B(02105): LAE118 (a novel PI3K pan-mutant selective inhibitor) First patient enrolled in Phase I clinical study.

LAEKNA-B (02105) announced that the group has commenced the recruitment of subjects for the Phase I clinical study ("Phase I clinical study") of LAE118 for the treatment of advanced solid tumors in China, and the first subject has been enrolled. In June 2026, the group entered into an exclusive licensing agreement ("License Agreement") with Vasque Bio, Inc. ("Vasque Bio"). Under the terms and conditions of the License Agreement, the group is entitled to receive a total of up to $527 million in non-refundable and non-creditable upfront and milestone payments, as well as a tiered royalty on net sales of LAE118 within the licensed areas calculated as a single-digit to double-digit percentage. The group is also entitled to receive, without any additional consideration, equity in Vasque Bio of up to a high double-digit percentage of issued common stock, or cash payments in lieu of such common stock. Should Vasque Bio enter into any qualifying strategic collaborations or acquisition transactions related to the use of LAE118 that meet specific conditions, the group shall be entitled to receive additional payments, with amounts reaching up to 50% of the value of the strategic transaction. Vasque Bio primarily focuses on the development of treatments for rare diseases, while the group focuses on developing tumor therapies for LAE118 outside the licensed areas. The group can leverage this opportunity to accelerate the global development and commercialization of LAE118 for a broader range of indications within the licensed areas and enhance downstream value creation (such as licensing, collaboration, or merger and acquisition exits). The company will continue to concentrate on specific therapeutic areas where it has accumulated deep expertise and extensive practical experience. To further improve the efficiency of the company's discovery research and shorten the preclinical development timeline, the company is accelerating the application of artificial intelligence (AI) in its discovery platform from target identification and lead optimization to predicting toxicology and screening clinical candidates.